SuperworthTriSalus Life Sciences price to sales ratio TLSI
Market value divided by revenue over the last twelve months, since 2024.
- Today, Oct 23, 2026
- 4.9×
- 2-year median
- 6.1×
- Against its 2-year history
- 9th
- percentile: 0 is its lowest day, 100 its highest
- 2-year range
- 3.7× to 9.2×
- Peer median
- 1.6×
TriSalus Life Sciences' price to sales ratio is 4.9× as of Oct 23, 2026.
That is below its 2-year median of 6.1×, lower than on 91% of days in the last 2 years.
Over that time it ranged from 3.7× in May 2026 to 9.2× in Dec 2025.
The median for 10 medical instruments and supplies stocks of a similar size is 1.6×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 4.9× | 3.7× | 7.7× |
| 2025 | 8.5× | 4.7× | 9.2× |
| 2024 | 5.5× | 4.4× | 6.8× |
Against its peers
Companies in Medical - Instruments & Supplies nearest TriSalus Life Sciences' size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| TLSITriSalus Life Sciences | 4.9× |
| UTMDUtah Medical Products | 6.5× |
| PDEXPro DEX | 2.6× |
| INFUInfuSystem | 1.9× |
| EMBCEmbecta | 0.4× |
| KEQUKewaunee Scientific | 0.3× |
| TCMDTactile Systems Technology | 1.5× |
| MDXGMimedx | 1.6× |
| MOVMovado | 1.0× |
| APTAlpha Pro Tech | 0.9× |
| IRMDIradimed | 12.7× |
| Peer median | 1.6× |
Where TriSalus Life Sciences ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on TriSalus Life Sciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.